Emcure Pharmaceuticals’ shares jumped close to 3% on Jan 7, reaching a fresh 52‑week high before slipping back to close slightly lower.
Recent Price Move
The stock climbed to ₹1,568.30, then trimmed gains to finish at ₹1,522. It’s up more than 12% in the past five days, over 22% in the last six months, and about 7% over the past year.
Weight‑Loss Injection Drive
In November, Emcure announced an exclusive partnership with Novo Nordisk India to distribute Poviztra, a 2.4 mg semaglutide injection for weight loss. The commercial launch followed in December, giving the stock a fresh catalyst.
Technical Outlook
Analyst Drumil Vithlani notes a strong bullish breakout from a consolidation phase, with higher volumes indicating new buying interest. The share now trades comfortably above major moving averages and the previous resistance at ₹1,500, which could act as support if the price pulls back.
- Support zone: ₹1,480 – ₹1,500
- Near‑term target: ₹1,580 – ₹1,620
- Key floor: ₹1,450
What Traders Might Do
Momentum indicators remain in the bullish range, and the Relative Strength Index (RSI) shows no signs of exhaustion. Vithlani suggests a “buy‑on‑dips” approach near the ₹1,480–₹1,500 area, with upside potential as long as the price stays above ₹1,450.
Disclaimer
Remember, this is perspective, not a prediction. Do your own research before making any investment decisions.